Clinical trials: Thromboembolic Disease
Breast Neoplasms, Venous Thromboembolism
Hemostatic Profiles of Endocrine Therapies for Breast Cancer
The aim of this prospective cohort study is to evaluate the modifications of the biological hemostatic profile associated with the use of endocrine therapy in women with breast cancer (tamoxifen or aromatase inhibitors).
- Trial name
- HEMOBREAST (NCT03381963)
- Where
- Switzerland
- Volunteers
- 100 people
- Sponsor
- University Hospital, Geneva
Venous Thromboembolic Disease
The Role of FDG-PET/CT Imaging in the Management of Patients With Thromboembolic Disorders (The PETVET Study)
This pilot study aims at validating 18F-flourodeoxyglucose positron emission tomography/computed tomography (FDG-PET/CT) in the detection and characterization of venous thromboembolism (VTE) in the entire human body, especially…
- Trial name
- PETVET (NCT01466426)
- Where
- 3 sites in Denmark
- Volunteers
- 40 people
- Sponsor
- Odense University Hospital
Venous Thrombosis, Pulmonary Embolism
Study of Rivaroxaban Use and Potential Adverse Outcomes in Routine Clinical Pratice (Netherlands)
This prospective cohort study will provide information about: characteristics of Rivaroxaban use in patients who are prescribed Rivaroxaban for the first time compared to patients who are prescribed Acenocoumarol for the first…
- Conditions
- Venous Thrombosis, Pulmonary Embolism, Atrial Fibrillation, Acute Coronary Syndrome
- Trial name
- NCT01947985
- Testing
- Rivaroxoban (Xarelto, Bay59-7939), Standard of care
- Where
- Netherlands
- Volunteers
- 208,958 people
- Sponsor
- Bayer
Thromboembolic Venous Disease
New Genetic Mutations in Thromboembolic Venous Disease Idiopathic. Study "FIT GENETIQUE".
Identify new genetic mutations predisposing to an increased risk of VTE by locating and / or identifying genes involved in subjects at high risk for thrombotic and in whom screening for detectable hereditary thrombophilia was…
- Trial name
- Fit-Génétique (NCT02841085)
- Testing
- Genetic sample
- Where
- France
- Volunteers
- 613 people
- Sponsor
- University Hospital, Brest
Pancreatic Cancer, Thromboembolism
Gemcitabine With or Without Dalteparin in Treating Patients With Locally Advanced or Metastatic Pancreatic Cancer
RATIONALE: Drugs used in chemotherapy, such as gemcitabine, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing.
- Trial name
- NCT00462852
- Testing
- dalteparin, gemcitabine hydrochloride, diagnostic laboratory biomarker analysis
- Where
- 8 sites in United Kingdom
- Volunteers
- 120 people
- Sponsor
- Hull University Teaching Hospitals NHS Trust
Cerebral Venous Thrombosis
Study of Rivaroxaban for CeREbral Venous Thrombosis
SECRET examines the safety of rivaroxaban versus standard-of-care for treatment of symptomatic cerebral venous thrombosis, initiated within 14 days of diagnosis.
- Trial name
- SECRET (NCT03178864)
- Testing
- Rivaroxaban, Standard of care
- Where
- 11 sites in Canada
- Volunteers
- 55 people
- Sponsor
- University of British Columbia
Venous Thromboembolism
Screening for Occult Malignancy in Idiopathic Venous Thromboembolism
Prospective controlled randomized study. Aim of this study is to assess the feasibility and sensitivity of CT scanning of the thorax, abdomen and pelvis for the detection of occult cancer in patients with idiopathic venous…
- Trial name
- NCT00361647
- Testing
- Diagnostic screening for occult malignancy
- Where
- Italy
- Sponsor
- University of Padova
Cancer-associated Thrombosis, Esophageal Cancer
A Randomized Phase II Open Label Study to Compare the Safety and Efficacy of Subcutaneous Dalteparin Versus Direct Oral Anticoagulants for Cancer-associated Venous Thromboembolism
This is an open label, multi-center, and randomized phase II trial designed to compare the safety and efficacy of direct oral anticoagulants and subcutaneous dalteparin in patients with acute venous thromboembolism and upper…
- Conditions
- Cancer-associated Thrombosis, Esophageal Cancer, Stomach Cancer, Hepatocellular Carcinoma
- Trial name
- PRIORITY (NCT03139487)
- Testing
- Rivaroxaban, Dalteparin, apixaban
- Where
- South Korea
- Volunteers
- 176 people
- Sponsor
- Asan Medical Center
Cerebral Venous Thrombosis
Direct Oral Anticoagulants for the Treatment of Cerebral Venous Thrombosis
Rationale: Patients with cerebral venous thrombosis (CVT) are currently treated with anticoagulants during 3-12 months after diagnosis, to prevent worsening of the CVT and recurrent thrombosis, and to promote venous…
- Trial name
- DOAC-CVT (NCT04660747)
- Testing
- Oral anticoagulant
- Where
- Netherlands
- Volunteers
- 1,300 people
- Sponsor
- Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)
Pulmonary Arterial Hypertension, Chronic Thromboembolic Pulmonary Hypertension
A Clinical Study to Investigate the Long-term Safety of the Drug Macitentan in Patients With Pulmonary Hypertension Who Were Previously Treated With Macitentan in Clinical Studies.
The aim of the trial is to study the long-term safety of macitentan and to provide continued treatment with macitentan to patients with pulmonary arterial hypertension (PAH) and Chronic thromboembolic pulmonary hypertension…
- Trial name
- UMBRELLA (NCT03422328)
- Testing
- macitentan
- Where
- 34 sites in Belarus, Belgium and 5 more
- Volunteers
- 151 people
- Sponsor
- Actelion
Venous Thromboembolism (VTE), Deep Vein Thrombosis (DVT)
Decision Aid for Anticoagulation Duration After Unprovoked Venous Thromboembolism
Venous thromboembolism (VTE), including deep vein thrombosis and pulmonary embolism, is a common condition that is typically treated with blood thinners (anticoagulants).
- Conditions
- Venous Thromboembolism (VTE), Deep Vein Thrombosis (DVT), Pulmonary Embolism
- Trial name
- DECIDE-VTE (NCT07659106)
- Testing
- DECIDE-VTE Patient Decision Aid
- Where
- 5 sites in Canada
- Volunteers
- 850 people
- Sponsor
- McGill University Health Centre/Research Institute of the McGill University Health Centre
Prevention of Venous Thromboembolism After Knee Arthroplasty
SHR-2004 for the Prevention of Venous Thromboembolism in Patients Undergoing Total Knee Arthroplasty
The purpose of the study is to evaluate the efficacy and safety of SHR-2004 in preventing venous thromboembolism after elective unilateral total knee arthroplasty
- Trial name
- NCT05752461
- Testing
- SHR-2004 injection, Enoxaparin sodium injection
- Where
- China
- Volunteers
- 353 people
- Sponsor
- Beijing Suncadia Pharmaceuticals Co., Ltd
Pulmonary Embolism
Crux Biomedical Evaluation of the Crux Inferior Vena Cava Filter System 3 ("RETRIEVE 3")
The purpose of this study is to determine if the Crux Vena Cava Filter System is safe and effective in preventing pulmonary embolism.
- Trial name
- RETRIEVE 3 (NCT01120522)
- Testing
- Inferior Vena Cava Filter
- Where
- 2 sites in Belgium
- Volunteers
- 17 people
- Sponsor
- Crux Biomedical
Acute Coronary Syndrome, Venous Thromboembolism
The Effect of Reduced Dose of Enoxaparin on the Outcomes of Treatment With Enoxaparin
We hypothesize that reduced dose of enoxaparin in elderly patients will result in reduced proportion of patients with therapeutic anti Xa activity and reduced clinical efficacy.
- Conditions
- Acute Coronary Syndrome, Venous Thromboembolism, Atrial Fibrillation, Hypercoagulability
- Trial name
- NCT00354796
- Where
- Israel
- Volunteers
- 500 people
- Sponsor
- Hadassah Medical Organization
Pediatric Venous Thromboembolism
Rivaroxaban in Pediatric Patients With DVT
Prospective interventional randomized controlled trial to assess safety and efficacy of rivaroxaban in pediatric patients with acute deep venous thrombosis.
- Trial name
- NCT07618988
- Testing
- Rivaroxaban, Enoxaparin, Heparin
- Where
- Egypt
- Volunteers
- 60 people
- Sponsor
- Ain Shams University
Pulmonary Embolism Acute
SCUBE-1 and VAP-1 Levels on Diagnosis Pulmonary Embolism
Acute pulmonary thromboembolism is a life-threatening disease. Clinical suspicion is essential for diagnosis because of lack of a specific finding for diagnosis of PTE.
- Trial name
- NCT06733961
- Testing
- SCUBE-1 and VAP-1
- Where
- Turkey (Türkiye)
- Volunteers
- 88 people, healthy volunteers welcome
- Sponsor
- Giresun University
Pulmonary Hypertension
PIMR and Pulmonary Vascular Disease
The findings from this innovative, first-in-man, prospective pilot study will elucidate the role of PIMR and RV-IMR in pre-capillary PH.
- Trial name
- NCT05843461
- Testing
- Pulmonary Index of Microcirculatory Resistance, Right Ventricle Index of Microcirculatory Resistance, Pulmonary artery OCT
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- University of California, Los Angeles
Prophylaxis of Venous Thromboembolic Events
Single IV Administration of TB-402 for Prophylaxis of Venous Thromboembolic Events (VTE) After Total Hip Replacement Surgery
The purpose of this study is to evaluate the safety and efficacy of two doses of TB-402 administered as a single intravenous infusion for the prevention of VTE in subjects undergoing total hip replacement surgery.
- Trial name
- NCT01344954
- Testing
- TB-402, Rivaroxaban
- Where
- 36 sites in Austria, Belgium and 7 more
- Volunteers
- 632 people
- Sponsor
- ThromboGenics
Foot Ankle Injuries, Anticoagulants and Bleeding Disorders
A Prospective Study in Chinese Patients With Lower Extremity Ankle Fracture of Oral Anticoagulants to Prevent Venous Thromboembolism (VTE)
Deep vein Thrombosis (Deep Venous Thrombosis, DVT) and Pulmonary Embolism, Pulmonary Embolism, PE) both collectively known as Venous thromboembolism (VTE) (Venous Thrombus Embolism, VTE), is a common clinical disease, and…
- Conditions
- Foot Ankle Injuries, Anticoagulants and Bleeding Disorders, Venous Thromboembolism
- Trial name
- NCT04128254
- Testing
- Apixaban Oral Tablet
- Where
- China
- Volunteers
- 1,000 people
- Sponsor
- Second Affiliated Hospital, Zhejiang University, School of Medicine
Atherosclerotic Vascular Disease, Coronary Arterial Disease (CAD)
Genetic Testing of CYP2C19 in Prognostic Evaluation of Long-Term Major Adverse Cardiac and Vascular Events
Several studies have shown that the efficacy of clopidogrel for secondary prevention of major adverse cardiovascular events (MACE), including acute coronary syndrome, depends on the polymorphism of the CYP2C19 gene.
- Conditions
- Atherosclerotic Vascular Disease, Coronary Arterial Disease (CAD), Atherosclerosis of Coronary Artery, Atherosclerosis of Arteries of the Extremities, Unspecified
- Trial name
- UF-GENOTYPE (NCT06855394)
- Where
- 2 sites in United States
- Volunteers
- 13,000 people
- Sponsor
- University of Florida
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.